Research in the last decade has expressed considerable optimism about the clinical
potential of psychedelics for the treatment of mental disorders. This optimism is reflected in …

Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

Design Open-label Randomized Randomized, double-blind, placebo-controlled
Randomized, double-blind, placebo-controlled Randomized, double-blind, placebo …

Psilocybin is being investigated as a treatment in adults with treatment-resistant depression
(TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for …

We aim to systematically review and meta-analyze the effectiveness and safety of
psychedelics [psilocybin, ayahuasca (active component DMT), LSD and MDMA] in treating …

Objective To determine the efficacy of psilocybin as an antidepressant compared with
placebo or non-psychoactive drugs. Design Systematic review and meta-analysis. Data …

Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention
in recent years for their potential therapeutic effects and unique mechanisms of action …

Background: Research on psilocybin has become increasingly popular during the current
psychedelic renaissance, which began in the early 1990s. Psilocybin's effects on mental …

Psychedelics are powerful psychoactive substances that alter perception and mood
processes. Their effectiveness in the treatment of psychiatric diseases was known before …

Major depression is an established risk factor for subsequent dementia, and depression in
late life may also represent a prodromal state of dementia. Considering current challenges …